Arcus Capital Partners’s iBio IBIO Stock Holding History

Arcus Capital Partners’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-88	Closed	-$46K	–	115
2021 Q3	$46K	Hold	88	–	–	0.02%	98
2021 Q2	$66K	Hold	88	–	–	0.03%	104
2021 Q1	$68K	Hold	88	–	–	0.01%	109
2020 Q4	$46K	Buy	+88	New	+$71.7K	0.01%	108
2017 Q2	–	Sell	-621	Closed	-$1.34M	–	106
2017 Q1	$1.34M	Hold	621	–	–	0.84%	19
2016 Q4	$1.23M	Hold	621	–	–	0.83%	18
2016 Q3	$1.71M	Buy	+621	New	+$1.95M	1.25%	10
2016 Q2	–	Sell	-201	Closed	-$569K	–	67
2016 Q1	$569K	Hold	201	–	–	0.41%	32
2015 Q4	$563K	Buy	+201	New	+$641K	0.41%	33

Other funds holding IBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arcus Capital Partners's IBIO Position: Q4 2021 in Review

Arcus Capital Partners sold out of iBio (IBIO) in Q4 2021, closing a stake of 88 shares — an estimated $46K sold.

Arcus Capital Partners first reported a position in IBIO in Q4 2015 and held it in 9 quarters. The position peaked at $1.71M in Q3 2016. 77 funds tracked by Wall St. Rank hold IBIO as of Q4 2021.

Arcus Capital Partners reported no remaining iBio position as of Q4 2021 after selling out during the quarter.
Arcus Capital Partners sold 88 iBio shares in Q4 2021, an estimated $46K.
Arcus Capital Partners first reported a position in iBio in Q4 2015 and held it in 9 quarters.
Arcus Capital Partners's iBio position peaked at $1.71M in Q3 2016.
77 funds tracked by Wall St. Rank held iBio as of Q4 2021.

Based on Arcus Capital Partners's 13F filing for Q4 2021, filed 28 Jan 2022.